SAN DIEGO, April 29 /PRNewswire-FirstCall/ -- Pharmacopeia, Inc.
(Nasdaq: ACCL) today announced that it plans to release its financial results
for the quarter ended March 31, 2004 before the Nasdaq Market opens on
Tuesday, May 4, 2004. The Company will conduct a conference call and an audio
webcast at 9:00 A.M. EDT on the same day.
Mark Emkjer, President of Accelrys Inc., will host the call. Forward-
looking and other material information may be discussed on this conference
call.
Conference call numbers are as follows:
Domestic callers: 800-360-9865
International callers: 973-317-1168
Webcast information can be accessed through: http://www.pharmacopeia.com
A replay of the conference call, which can be accessed by dialing toll-
free 1-800-428-6051, and outside the U.S. 1-973-709-2089, will be available
for 2 weeks. The access code for the replay is 354072.
Accelrys (http://www.accelrys.com) is a leader in enabling science and technology
that accelerates and improves the drug discovery and chemical development
processes. Accelrys develops and commercializes molecular modeling and
simulation software for the life sciences and materials research markets,
cheminformatics and decision support systems, and bioinformatics tools
including gene sequence analysis. Accelrys is headquartered in San Diego,
California.
Pharmacopeia Drug Discovery (PDD) (http://www.pharmacopeia.com) is a chemistry-
based collaborative drug discovery company, focused on the creation of new
small molecule therapeutics. Using proprietary technologies and processes,
PDD's experienced scientists identify and optimize novel drug candidates
through research collaborations with major pharmaceutical and biological
companies and through its own internally-funded drug discovery programs.
PDD is headquartered in Princeton, New Jersey.
When used anywhere in this document, the words "expects," "believes,"
"anticipates," "estimates" and similar expressions are intended to identify
forward-looking statements. Forward-looking statements herein may include
statements addressing future financial and operating results of Pharmacopeia
and PDD. Pharmacopeia and PDD have based these forward-looking statements on
its current expectations about future events. Such statements are subject to
risks and uncertainties including, but not limited to, the successful
implementation of Pharmacopeia's and PDD's strategic plans, the development by
each company and market acceptance of new products, the establishment by PDD
of drug discovery collaborations and the results of PDD's internal proprietary
drug discovery programs, the obsolescence of existing products, the resolution
of existing and potential future patent issues, additional competition,
changes in economic conditions and other risks described in documents
Pharmacopeia and PDD have filed with the Securities and Exchange Commission,
including PDD's registration statement on Form 10 and subsequent filings under
the Securities Exchange Act of 1934, and Pharmacopeia's most recent report on
Form 10-K and subsequent filings under the Securities Exchange Act of 1934.
All forward-looking statements in this document are qualified entirely by the
cautionary statements included in this document and such filings. These risks
and uncertainties could cause actual results to differ materially from results
expressed or implied by forward-looking statements contained in this document.
These forward-looking statements speak only as of the date of this document.
Each of Pharmacopeia and PDD disclaim any undertaking to publicly update or
revise any forward-looking statements contained herein to reflect any change
in its expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
Pharmacopeia/Accelrys Contact:
John J. Hanlon
Chief Financial Officer
Pharmacopeia, Inc.
(858) 799-5000
Pharmacopeia Drug Discovery Contact:
Brian M. Posner
Vice President, Finance
Pharmacopeia Drug Discovery, Inc.
(609) 452-3600
irreq@pharmacopeia.com
| |
SOURCE Pharmacopeia, Inc.
 back to top
Related links:
http://www.pharmacopeia.com
CONTACT:
Pharmacopeia/Accelrys: John J. Hanlon, Chief
Financial Officer, Pharmacopeia, Inc., +1-858-799-5000; or
Pharmacopeia Drug Discovery: Brian M. Posner, Vice President,
Finance, Pharmacopeia Drug Discovery, Inc., +1-609-452-3600,
irreq@pharmacopeia.com
| |
|
